# QURE

**Deep-research report — K3vl4r**  
**Symbols:** QURE  
**Sources:** 20  
**Published:** 2026-08-29  
**Canonical:** https://app.k3vl4r.com/research/deep-research-qure-2761

---

# uniQure NV (QURE) — Research Summary as of August 28, 2026

## The Core Catalyst Behind the Move

The primary driver of QURE's dramatic move has been **a reversal by the FDA regarding the BLA (Biologics License Application) pathway for AMT-130**, uniQure's gene therapy for Huntington's disease. According to [[2]](https://seekingalpha.com/article/4916037-uniqure-amt-130s-fda-path-reaffirms-my-bull-case) and [[3]](https://www.top1markets.com/news/uniqure-qure-stock-amt130-fda-catalyst-2026), the FDA reopened the AMT-130 BLA path, which was described as "a stark reversal from late 2025 and early 2026, when the FDA expressed skepticism regarding the reliance on external [data]" [[3]](https://www.top1markets.com/news/uniqure-qure-stock-amt130-fda-catalyst-2026). This news broke around **June 17, 2026**, and shares surged approximately **78.44%** on that day alone [[5]](https://finviz.com/stock?t=QURE). The Wall Street Journal covered the story under the headline "uniQure Shares Surge After FDA's Reversal on Gene Therapy" [[5]](https://finviz.com/stock?t=QURE).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-qure-2761 (free to sign up)._